US · XBIT
XBiotech Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Austin, TX 78744
- Website
- xbiotech.com
Price · as of 2024-12-31
$2.55
Market cap 68.9M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $7.23 | ||||
| 2016 | $13.19 | ||||
| 2017 | $4.07 | ||||
| 2018 | $9.27 | ||||
| 2019 | $9.59 | ||||
| 2020 | $17.20 | ||||
| 2021 | $8.98 | $80.71 | $6.37 | $0.00 | $27.55 |
| 2022 | $3.34 | $64.05 | $6.02 | $2.49 | $72.06 |
| 2023 | $6.40 | $32.75 | |||
| 2024 | $3.25 |
AI valuation
Our deep-learning model estimates XBiotech Inc.'s (XBIT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $2.55
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| XBIT | XBiotech Inc. | $2.55 | 68.9M | — | — | — | — | -2.57 | 0.54 | — | 1.76 | -4.62 | 0.54 | 0.00% | — | — | -19.21% | -219.51% | -18.10% | 0.06 | -52.63 | 11.56 | 11.49 | 4.51 | 5556.00% | — | 6905.00% | -32.59% | -2.05 | -166.91% | 0.00% | 0.00% | 0.00% | 1.49 | 1.97 | — | 3.15 |
| ACET | Adicet Bio, Inc. | $7.25 | 69.44M | — | — | — | — | -0.60 | 0.37 | — | 0.81 | — | 0.37 | 0.00% | — | — | -65.65% | -433.12% | -54.79% | 0.09 | -31903.75 | 9.29 | 9.09 | 0.35 | -5982.00% | — | -477.00% | -133.68% | -4.76 | -317.32% | 0.00% | 0.00% | 0.00% | 0.70 | 0.95 | — | -2.95 |
| ACRV | Acrivon Therapeutics, Inc… | $1.51 | 47.65M | — | — | — | — | -2.63 | 1.20 | — | -0.46 | — | 1.20 | 0.00% | — | — | -54.07% | 26706.29% | -48.11% | 0.02 | — | 10.55 | 10.43 | 0.45 | -2336.00% | — | 5579.00% | -32.26% | -3.81 | 20490.12% | 0.00% | 0.00% | 2.26% | -0.41 | -0.53 | — | 4.53 |
| ADAG | Adagene Inc. | $2.96 | 111.61M | +945% | -54% | — | +2,625% | -2.19 | 1.45 | 708.59 | -0.20 | -2.88 | 1.45 | -797.49% | -34835.42% | -32386.45% | -55.21% | 216.17% | -32.61% | 0.37 | -42.20 | 2.30 | 2.23 | 2.11 | 7593.00% | -9943.00% | 419.00% | -40.66% | -0.78 | 178.88% | 0.00% | 0.00% | 0.00% | -0.18 | -0.22 | 62.29 | -4.41 |
| CRVO | CervoMed Inc. | $3.99 | 36.92M | — | — | — | — | -1.10 | 0.46 | — | 1.16 | -0.75 | 0.46 | 0.00% | — | — | -69.95% | 26851.40% | -61.41% | 0.00 | — | 11.11 | 10.61 | 0.49 | 14634.00% | — | 12189.00% | -92.65% | -4.26 | 24352.48% | 0.00% | 0.00% | 6.76% | 1.16 | 1.28 | — | 0.16 |
| FBIO | Fortress Biotech, Inc. | $3.42 | 106.15M | +410% | -82% | — | +1,342% | -0.26 | 1.41 | 0.55 | -0.49 | — | -3.51 | 63.80% | -191.38% | -79.75% | -533.80% | -308.14% | -77.53% | 3.34 | -11.12 | 1.27 | 0.95 | -0.18 | -6824.00% | -3176.00% | -3017.00% | -297.40% | -1.12 | -265.74% | 14.72% | -3.90% | 14.72% | -0.46 | -0.53 | 0.88 | -9.03 |
| GANX | Gain Therapeutics, Inc. | $2.61 | 100.39M | +1,143% | — | — | — | -2.11 | 5.86 | — | -1.64 | — | 5.97 | 0.00% | — | — | -204.95% | 729.11% | -132.83% | 0.09 | — | 2.97 | 2.85 | 0.48 | -4795.00% | -10000.00% | 8.00% | -43.93% | -4.83 | 677.01% | 0.00% | 0.00% | 0.00% | -1.64 | -1.76 | — | -8.76 |
| LITS | Lite Strategy, Inc. | $1.13 | 41.55M | +12,712% | — | — | — | -1.77 | 1.66 | — | -0.60 | — | 1.66 | 0.00% | — | — | -63.84% | 545.04% | -53.45% | 0.00 | — | 13.50 | 13.30 | 1.05 | -18951.00% | -10000.00% | -5871.00% | -73.96% | -15.39 | 650.87% | 0.00% | 0.00% | 50.76% | -0.58 | -0.49 | — | -20.49 |
| NTRB | Nutriband Inc. | $4.44 | 54.06M | +340% | -57% | — | — | -4.78 | 7.79 | 23.39 | -4.51 | -10.98 | 11.26 | 32.68% | -312.62% | -489.86% | -162.94% | -157.60% | -139.89% | 0.03 | -312.51 | 4.88 | 4.46 | 0.41 | 4348.00% | 262.00% | 3184.00% | -9.43% | -4.71 | -111.17% | 0.00% | 0.00% | 8.03% | -6.87 | -9.73 | 21.47 | 19.59 |
| RLMD | Relmada Therapeutics, Inc… | $4.56 | 334.4M | — | — | — | — | -0.11 | 0.24 | — | 0.43 | — | 0.24 | 0.00% | — | — | -132.33% | 824.32% | -111.57% | 0.00 | — | 4.45 | 4.36 | 0.05 | -1921.00% | — | 19.00% | -597.84% | -5.03 | 508.56% | 0.00% | 0.00% | 0.00% | 0.43 | 0.70 | — | -24.19 |
| TCRX | TScan Therapeutics, Inc. | $1.06 | 60.15M | +2,649% | +18% | — | +7,924% | -1.74 | 0.92 | 78.74 | -0.24 | — | 0.92 | 100.00% | -4787.68% | -4527.66% | -65.08% | -271.01% | -39.64% | 0.40 | -36.91 | 8.14 | 8.07 | 0.68 | -1618.00% | -8662.00% | 7774.00% | -51.70% | -3.08 | -230.45% | 0.00% | 0.00% | 18.21% | -0.22 | -0.25 | 10.30 | -0.75 |
About XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
- CEO
- Sushma Shivaswamy
- Employees
- 92
- Beta
- 0.85
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $2.55) − 1 = — (DCF, example).